Figure 2.

Responses to ‘reason for use of combination therapy’ recorded for 416 patients treated with Combo SSA or Combo DA. Data from earliest (first) case form reported. 48% completed questionnaire at baseline, 52% after pegvisomant start. Choices were listed; answered by investigators as ‘yes’ or ‘no’. Multiple responses were allowed (544 different responses in 416 patients on first report).